However, a recent randomized controlled trial utilizing a therapeutic vaccine regimen in HIV infected patients who began cART early during the course of infection, showed a limited induction of anti-viral CD8+ T cells, no significant effects on the kinetics of viral rebound, and no reduction in the viral reservoir post discontinuation of ART (194). The gene discussed is CD8A; the disease is infection.